LogicBio Therapeutics, Inc. (LOGC) News

LogicBio Therapeutics, Inc. (LOGC): $1.54

-0.03 (-1.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LOGC News Items

LOGC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LOGC News Highlights

  • For LOGC, its 30 day story count is now at 5.
  • Over the past 13 days, the trend for LOGC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest LOGC News From Around the Web

Below are the latest news stories about LogicBio Therapeutics Inc that investors may wish to consider to help them evaluate LOGC as an investment opportunity.

LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that president and chief executive officer, Fred Chereau, will participate in a fireside chat at the virtual H.C. Wainwright Bioconnect Conference being held January 10-13, 2022. The pre-recorded presentation will be available for on-demand viewing beginning at 7:00 a.m. ET on Monday, January 10, 2022.

Yahoo | January 4, 2022

LogicBio Therapeutics (NASDAQ:LOGC) Price Target Lowered to $16.00 at Chardan Capital

LogicBio Therapeutics (NASDAQ:LOGC) had its target price lowered by Chardan Capital from $20.00 to $16.00 in a research note issued to investors on Thursday morning, PriceTargets.com reports. The brokerage currently has a buy rating on the stock. LOGC has been the topic of several other reports. Zacks Investment Research cut LogicBio Therapeutics from a hold []

Dakota Financial News | December 24, 2021

H.C. Wainwright Keeps a Buy Rating on Logicbio Therapeutics (LOGC)

H.C. Wainwright analyst Edwin Zhang maintained a Buy rating on Logicbio Therapeutics (LOGC – Research Report) today and set a price target of $15.00. The company's shares closed last Wednesday at $2.33. According to TipRanks.com, Zhang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.9% and a 11.1% success rate. Zhang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Calliditas Therapeutics, and Reneo Pharmaceuticals. Currently, the analyst consensus on Logicbio Therapeutics is a Strong Buy with an average price target of $13.00. See the top stocks recommended by analysts >> The company has a one-year high of $9.

Catie Powers on TipRanks | December 22, 2021

LogicBio Therapeutics Provides Business Updates

LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company, today provided updates around its SUNRISE Phase 1/2 clinical trial and development pipeline, and announced the appointment of Susan R. Kahn to its Board of Directors.

Yahoo | December 22, 2021

State Street Corp Lowers Stake in LogicBio Therapeutics, Inc. (NASDAQ:LOGC)

State Street Corp reduced its position in shares of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) by 89.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,807 shares of the companys stock after selling 208,732 shares during the quarter. State Street Corp []

Transcript Daily | December 12, 2021

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Shares Acquired by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. boosted its position in shares of LogicBio Therapeutics, Inc. (NASDAQ:LOGC) by 59.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,030 shares of the companys stock after purchasing an additional 20,423 shares during the period. [] The post LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Shares Acquired by Goldman Sachs Group Inc. appeared first on ETF Daily News .

ETF Daily News | December 11, 2021

Analysts Set LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Price Target at $13.00

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has been given a consensus rating of Buy by the six research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that []

Transcript Daily | November 24, 2021

Walleye Trading LLC Purchases Shares of 12,411 LogicBio Therapeutics, Inc. (NASDAQ:LOGC)

Walleye Trading LLC acquired a new stake in LogicBio Therapeutics, Inc. (NASDAQ:LOGC) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 12,411 shares of the companys stock, valued at approximately $55,000. Other hedge funds also recently added to or reduced their stakes in the company. Citadel Advisors []

Transcript Daily | November 24, 2021

LogicBio Therapeutics (LOGC) Investment Analysts Weekly Ratings Updates

A number of firms have modified their ratings and price targets on shares of LogicBio Therapeutics (NASDAQ: LOGC) recently: 11/18/2021 LogicBio Therapeutics was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines []

Dakota Financial News | November 22, 2021

Jefferies Financial Group Research Analysts Lift Earnings Estimates for LogicBio Therapeutics, Inc. (NASDAQ:LOGC)

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Analysts at Jefferies Financial Group raised their FY2021 earnings estimates for LogicBio Therapeutics in a research report issued to clients and investors on Wednesday, November 17th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of ($1.36) for the year, up from their []

Dakota Financial News | November 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6348 seconds.